Call 1 (888) 460-6556 to speak with a counselor.

Conclusions
Severe and moderate hepatic impairment significantly increased exposure of naloxone and to a lesser extent of buprenorphine. Therefore, buprenorphine/naloxone combination products should generally be avoided in patients with severe hepatic impairment and may not be appropriate for patients with moderate hepatic impairment. However, buprenorphine/naloxone products may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone [Registered at ClinicalTrials.gov as NCT01846455] (Source: Clinical Pharmacokinetics)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

Call 1 (888) 460-6556 to speak with a counselor.

CONCLUSIONS: Evaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00316277.
PMID: 25562462 [PubMed – as supplied by publisher] (Source: Journal of Clinical Psychiatry)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

{ Comments on this entry are closed }

Complete Care Medical Center Now Offering Same Week Appointments for…

December 29, 2014

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best […]

Read the full article →

ZUBSOLV (Buprenorphine Hydrochloride And Naloxone Hydrochloride) Tablet, Orally Disintegrating [Orexo US, Inc.]

December 24, 2014

Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST)) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Dose and other factors associated with decreased pain intensity among patients initiating buprenorphine/naloxone

December 18, 2014

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Primary care buprenorphine detoxification vs. maintenance for prescription opioid dependence

December 18, 2014

Aims: The favorable clinical characteristics and improved treatment outcomes for prescription opioid dependent (POD) patients, and modest severity of withdrawal symptoms with buprenorphine/naloxone (bup/nx), have led physicians to offer detoxification with bup/nx for POD patients. We sought to determine whether bup/nx stabilization followed by detoxification (DTX) or maintenance (MTN) leads to greater reduction in illicit […]

Read the full article →

Buprenorphine/naloxone abuse and diversion: Film rates are less than tablet rates

December 18, 2014

This study extends the comparison of diversion and abuse rates between buprenorphine sublingual formulations. (Source: Drug and Alcohol Dependence)

Read the full article →

Cognitive behavioral therapy improves treatment outcome for prescription opioid users in primary care based buprenorphine/naloxone treatment

December 18, 2014

Aims: To assess whether response to Cognitive Behavioral Therapy (CBT) differed between primarily prescription opioid users (POU) and primarily heroin users (HU) receiving primary care buprenorphine/naloxone (BUP) treatment with physician management (PM). (Source: Drug and Alcohol Dependence)

Read the full article →

Medicaid budget impact of generic buprenorphine/naloxone tablet

December 18, 2014

Aims: The buprenorphine/naloxone (Bup/Nal)combination for the treatment of opioid dependence is available in two forms – sublingual film and tablet. Recent studies demonstrated that treatment with film leads to improved treatment retention and lower healthcare costs. In March 2013 generic tablets appeared on the market. A budget impact model was built to compare health care […]

Read the full article →

Feasibility of very low dose naltrexone and buprenorphine transition from opioid use to extended-release naltrexone

December 18, 2014

Aims: The approval of extended release injectable naltrexone suspension (XR-NTX) has introduced a new option for treating opioid addiction, but the absence of physiological opioid dependence is a necessary and challenging first step for starting therapy. Outpatient detoxification gives poor results and inpatient detoxification is either unavailable or too brief for the physiological effects of […]

Read the full article →